XOMA Royalty Corporation

NasdaqGM:XOMA Stock Report

Market Cap: US$319.7m

XOMA Royalty Past Earnings Performance

Past criteria checks 0/6

XOMA Royalty's earnings have been declining at an average annual rate of -47.7%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 9.5% per year.

Key information

-47.7%

Earnings growth rate

-44.9%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-9.5%
Return on equity-35.3%
Net Margin-164.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties

Oct 15

News Flash: Analysts Just Made A Notable Upgrade To Their XOMA Royalty Corporation (NASDAQ:XOMA) Forecasts

Aug 14
News Flash: Analysts Just Made A Notable Upgrade To Their XOMA Royalty Corporation (NASDAQ:XOMA) Forecasts

Health Check: How Prudently Does XOMA Royalty (NASDAQ:XOMA) Use Debt?

Aug 02
Health Check: How Prudently Does XOMA Royalty (NASDAQ:XOMA) Use Debt?

XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares

Jun 29

Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?

Apr 03
Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?

Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?

Sep 01
Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?

Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates

Aug 11
Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates

XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M

Aug 04

Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically

May 08
Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically

Xoma Gets The Spotlight

Sep 02

Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade

Aug 20
Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade

We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right

May 13
We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right

Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?

May 11
Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?

XOMA EPS misses by $0.55, misses on revenue

May 06

XOMA gets milestone payment from Janssen Biotech

May 03

XOMA's (NASDAQ:XOMA) Earnings Are Of Questionable Quality

Mar 17
XOMA's (NASDAQ:XOMA) Earnings Are Of Questionable Quality

Analysts Are More Bearish On XOMA Corporation (NASDAQ:XOMA) Than They Used To Be

Mar 16
Analysts Are More Bearish On XOMA Corporation (NASDAQ:XOMA) Than They Used To Be

Is XOMA Corporation (NASDAQ:XOMA) Popular Amongst Institutions?

Mar 09
Is XOMA Corporation (NASDAQ:XOMA) Popular Amongst Institutions?

Did You Miss XOMA's (NASDAQ:XOMA) Impressive 140% Share Price Gain?

Feb 02
Did You Miss XOMA's (NASDAQ:XOMA) Impressive 140% Share Price Gain?

XOMA: A Royalty Aggregator To Watch

Jan 04

XOMA (NASDAQ:XOMA) Has Debt But No Earnings; Should You Worry?

Dec 29
XOMA (NASDAQ:XOMA) Has Debt But No Earnings; Should You Worry?

XOMA prices $22M offering of series A cumulative perpetual preferred stock

Dec 11

Revenue & Expenses Breakdown

How XOMA Royalty makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:XOMA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2422-35350
30 Jun 2415-24330
31 Mar 246-42280
31 Dec 235-46260
30 Sep 234-32260
30 Jun 234-31240
31 Mar 233-30240
31 Dec 226-23230
30 Sep 224010210
30 Jun 224110210
31 Mar 224112190
31 Dec 21388200
30 Sep 21301190
30 Jun 21296180
31 Mar 21296170
31 Dec 20299170
30 Sep 202-13170
30 Jun 2011-9200
31 Mar 2011-10210
31 Dec 1918-2210
30 Sep 1920-2210
30 Jun 1912-8200
31 Mar 1913-6190
31 Dec 185-13190
30 Sep 189-11210
30 Jun 18449240
31 Mar 185318240
31 Dec 17536240
30 Sep 1748-112343
30 Jun 1712-392043
31 Mar 172-611943
31 Dec 166-541843
30 Sep 1653-111911
30 Jun 165512023
31 Mar 1657-72037
31 Dec 1555-212150
30 Sep 1512-532052
30 Jun 1515-672053
31 Mar 1518-552050
31 Dec 1419-382051
30 Sep 1427-832186
30 Jun 1428-992154
31 Mar 1429-1042062
31 Dec 1335-1241847

Quality Earnings: XOMA is currently unprofitable.

Growing Profit Margin: XOMA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: XOMA is unprofitable, and losses have increased over the past 5 years at a rate of 47.7% per year.

Accelerating Growth: Unable to compare XOMA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XOMA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: XOMA has a negative Return on Equity (-35.33%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:27
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

XOMA Royalty Corporation is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ritu BaralCanaccord Genuity
Jason KantorCredit Suisse
Joseph PantginisH.C. Wainwright & Co.